ドイツの遺伝性疾患、癌、法医学的・親子鑑定分子診断検査市場

◆英語タイトル:Germany Genetic Diseases, Cancer, Forensic and Paternity Molecular Diagnostic Testing Markets: Country Forecasts, Emerging Technologies, Competitive Landscape
◆商品コード:VPMD8232
◆発行会社(調査会社):Venture Planning Group
◆発行日:2014年7月
◆ページ数:407
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:ドイツ
◆産業分野:医療
◆販売価格オプション(消費税別)
Local License(同一国内共有可)USD1,850 ⇒換算¥210,900見積依頼/購入/質問フォーム
Global License(複数国内共有可)USD3,900 ⇒換算¥444,600見積依頼/購入/質問フォーム
DataPack(データのみ)USD1,200 ⇒換算¥136,800見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はVenture Planning Group社の日本における正規販売代理店です。Venture Planning Group社の概要及び新刊レポートはこちらでご確認いただけます。
【レポートの概要】

Complete report $1,850.  DataPack (test volumes, sales forecasts, supplier shares) $1,200.  The report is available by section, market segment, and can be custom-tailored to your specific information needs and budget. 

This new study from Venture Planning Group contains 407 pages, and is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities for molecular diagnostic technologies and products in testig for genetic diseases, cancer, as well as forensic and paternity/HLA typing applications during the next five years. 

Report Highlights

- Market shares of leading suppliers
- Business and technological trends in major markets
- Five-year test volume and sales forecasts
- Market shares of leading competitors
- Feature comparison of major analyzers
- Strategic profiles of leading market players and start-up firms developing innovative products
- Specific product and business opportunities for instrument and consumable suppliers.

Rationale

Genetic Diseases, Cancer, Forensic and Paternity molecular diagnostic testing markets are among the most rapidly growing segments of the in vitro diagnostics industry.  The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches.  The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods.  In order to successfully capitalize on the opportunities presented by these markets, many companies are already exploiting new molecular technologies as corporate strategic assets, managed in support of business and marketing strategies.  Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostic companies during the next five years.

Germany Market Overview

- Laboratories performing DNA sequencing and molecular diagnostic testing by country and market segment.

- Five-year test volume and sales projections.

Market Segmentation Analysis

- Five-year test volume and sales projections:

- Infectious Diseases        – Forensic Testing
- Cancer                            – Paternity Testing/HLA Typing
- Genetic Diseases            – Others

- A comprehensive analysis of the sequencing market by laboratory segment.
  
- Detailed market segmentation analysis, including review of the market dynamics, trends,
  structure, size, growth and major suppliers.

Product/Technology Review

- Comparison of the major molecular diagnostic analyzers.

- Extensive review of molecular diagnostic technologies, test formats, detection methodologies,
  trends in testing automation and over target/signal amplification methods.

- Worldwide listings of companies, universities and research centers developing new molecular
   diagnostic technologies and products.

Competitive Assessments

- Extensive strategic assessments of major suppliers and emerging market entrants,
  including their sales, product portfolios, marketing tactics, collaborative arrangements and
  new technologies/products in R&D.
  
   – Abbott
   – Affymetrix
   – Agilent Technologies
   – Applied Gene Technologies
   – Arca/Nuvelo
   – Beckman Coulter/Danaher
   – Becton Dickinson
   – Biokit
   – BioMerieux
   – Bio-Rad
   – Biotest
   – Caliper
   – Cepheid
   – Decode
   – Diadexus
   – Eiken
   – Enzo[u]
[/u]   – Exact Sciences
   – Fujirebio/Innogenetics
   – Grifols
   – Hologic/Gen-Probe[u]
[/u]   – Illumina
   – Kreatech
   – Li-Cor Biosciences
   – Life Technologies/Thermo Fisher
   – Monogram Biosciences
   – Myriad Genetics
   – Nanogen/Elitech
   – Orchid CellMark[u]
[/u]   – Ortho-Clinical Diagnostics[u]
[/u]   – Proteome Sciences[u]
[/u]   – Qiagen              
   – Roche[u]
[/u]   – Scienion
   - Sequenom
   - Shimadzu
   - Siemens
   - Sierra Molecular
   - Takara Bio
   - Tecan Group

- Comprehensive listings of companies developing and marketing molecular
  diagnostic products, by test and application.

Opportunities and Strategic Recommendations

- Specific new product development opportunities with potentially significant market appeal
  during the next five years.

- Design criteria for new products.

- Alternative market penetration strategies.

- Potential market entry barriers and risks.

- Business planning issues and concerns.

Contains 407 pages

【レポートの目次】

※目次は次のPDFファイルをご確認ください。

http://www.vpgcorp.com/webfiles/DNA/TOCLOT%20GermanyGeneticDiseasesCancerForensicandPaternityMolecularDiagnosticTestingMarkets.pdf



★調査レポート[ドイツの遺伝性疾患、癌、法医学的・親子鑑定分子診断検査市場]販売に関する免責事項
★調査レポート[ドイツの遺伝性疾患、癌、法医学的・親子鑑定分子診断検査市場]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆